Exagen says co, janssen biotech entered into amendment to co-promotion agreement

Exagen inc - on june 25, co, janssen biotech, inc. entered into an amendment to co-promotion agreement.exagen - predetermined average baseline for total prescribed units of simponi for each remaining quarter in 2020 was adjusted to about y 26,000 units/quarter.exagen - for each of q3, q4 2020, to get minimum promotion fee of $0.3 million and fee will be capped at 5% above adjusted predetermined baseline.exagen - term of co-promotion agreement continues to expire on dec 31, 2021.
XGN Ratings Summary
XGN Quant Ranking